Feb 25, 2026 12:03PM
Feb 25, 2026 07:25AM
Feb 14, 2026 10:00AM
Feb 3, 2026 11:38AM
Dec 17, 2025 02:14AM
Nov 5, 2025 06:38AM
Sep 8, 2025 07:01AM Biodexa enrolls first patients in Phase 3 trial for FAP treatment
Aug 5, 2025 06:38AM
Jul 28, 2025 07:00AM
Jul 8, 2025 08:03AM
Jul 3, 2025 04:19AM
Jun 16, 2025 07:35AM
Jun 10, 2025 06:21AM
Jun 6, 2025 10:01AM Recursion (RXRX) and MIT researchers unveils Boltz-2 biomolecular model
May 6, 2025 03:18PM
May 6, 2025 05:40AM
May 5, 2025 06:31AM
Apr 16, 2025 08:42AM
Apr 8, 2025 08:04AM
Mar 18, 2025 08:03AM
Feb 28, 2025 02:06PM TD Cowen Reiterates Hold Rating on Recursion Pharmaceuticals (RXRX)
Feb 28, 2025 06:36AM
Feb 18, 2025 11:10AM
Feb 14, 2025 11:24AM
Feb 5, 2025 05:27PM
Jan 7, 2025 09:15AM
Dec 20, 2024 05:00AM
Nov 20, 2024 03:13PM KeyBanc Reiterates Overweight Rating on Recursion Pharmaceuticals (RXRX)
Nov 13, 2024 09:09AM
Nov 12, 2024 04:55PM
Nov 7, 2024 04:32PM
Oct 22, 2024 08:03AM
Oct 2, 2024 02:17PM
Oct 2, 2024 08:02AM
Sep 4, 2024 07:12AM Recursion Pharmaceuticals (RXRX) PT Lowered to $11 at Needham
Sep 3, 2024 03:00PM
Sep 3, 2024 02:54PM
Sep 3, 2024 11:50AM
Sep 3, 2024 08:19AM
Sep 3, 2024 08:00AM
Aug 8, 2024 07:41AM
Aug 8, 2024 07:37AM Recursion Pharmaceuticals, Inc. (RXRX) Misses Q2 EPS by 2c
Jul 9, 2024 05:17AM
Jun 27, 2024 05:45AM
Jun 26, 2024 04:56PM
Jun 26, 2024 04:07PM
Jun 26, 2024 08:59AM
Feb 12, 2024 12:21PM
Jan 29, 2024 04:01PM Form SC 13G RECURSION PHARMACEUTICAL Filed by: ARK Investment Management LLC
Nov 28, 2023 09:09AM

353,174 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All